Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

We are currently developing three product candidates under our INOpulse platform, a proprietary pulsatile nitric oxide delivery system for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).